COBRRA DELIVERS THE FIRST HEAD-TO-HEAD DOAC COMPARISON IN VTE

For over a decade, the question of whether to use apixaban or rivaroxaban for treating acute venous thromboembolism (VTE) has remained. Both are considered efficacious. But it’s now clear that one is safer than the other. COBRA Trial | N Engl J Med